Stephanie O'Malley, PA
Behavioral Neurology & Neuropsychiatry · Amherst, NYNPI 1366177420
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 575 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 16.0% — the pattern of someone who eats at a lot of different presentations.
Across 575 payments — averaging $23.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Neurocrine Biosciences, Inc.$1K
- AbbVie$1K
- Lundbeck LLC$932
- plus $5K from 25 others
What the payments were for
- Food & beverage$13,15698%
- Education$2172%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 74 | $2,144 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 60 | $1,471 |
| Otsuka America Pharmaceutical, Inc. | 63 | $1,418 |
| Neurocrine Biosciences, Inc. | 50 | $1,255 |
| AbbVie | 43 | $1,032 |
| Lundbeck LLC | 79 | $932 |
| Axsome Therapeutics, Inc. | 26 | $715 |
| Johnson & Johnson | 15 | $668 |
| Vanda Pharmaceuticals Inc. | 31 | $664 |
| Alkermes, Inc. | 26 | $527 |
| E.r. Squibb & Sons, L.L.C. | 13 | $424 |
| Idorsia Pharmaceuticals US Inc | 21 | $272 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $246 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $210 |
| Livanova USA, Inc. | 6 | $206 |
| Janssen Scientific Affairs, LLC | 3 | $182 |
| Corium, LLC | 8 | $150 |
| Lilly USA, LLC | 2 | $135 |
| Supernus Pharmaceuticals, Inc. | 7 | $135 |
| Bausch Health US, LLC | 7 | $134 |
| Acadia Pharmaceuticals Inc | 7 | $132 |
| Indivior Inc. | 5 | $102 |
| Noven Therapeutics, LLC | 3 | $51 |
| Mallinckrodt Hospital Products Inc. | 1 | $33 |
| UCB, Inc. | 2 | $31 |
| ITF Therapeutics LLC | 1 | $26 |
| Collegium Pharmaceutical, Inc. | 1 | $19 |
| Arbor Pharmaceuticals, Inc. | 1 | $17 |
| Luye Pharma (USA) Ltd. | 1 | $14 |
| Novocure Inc. | 1 | $13 |
| Upsher-smith Laboratories LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AUSTEDO$523
- SPRAVATO$505
- CAPLYTA$488
- VRAYLAR$350
- Austedo XR$342
- REXULTI$237
- COBENFY$125
- Auvelity$112
- INGREZZA$112
- MOUNJARO$111
- SUNOSI$109
- ABILIFY MAINTENA$107
- ABILIFY ASIMTUFII$107
How this compares
Too few behavioral neurology & neuropsychiatry providers in New Yorkto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 58 | $479,176 |
| Austedo XrDeutetrabenazine | 14 | $231,488 |
| NuplazidPimavanserin Tartrate | 28 | $197,926 |
| AustedoDeutetrabenazine | 11 | $170,896 |
| VraylarCariprazine Hcl | 91 | $145,156 |
| RexultiBrexpiprazole | 62 | $96,847 |
| CaplytaLumateperone Tosylate | 57 | $96,151 |
| TrintellixVortioxetine Hydrobromide | 100 | $75,343 |
| NuedextaDextromethorphan Hbr/Quinidine | 37 | $64,449 |
| Abilify MaintenaAripiprazole | 15 | $37,644 |
| AristadaAripiprazole Lauroxil | 13 | $31,853 |
| AuvelityDextromethorphan Hbr/Bupropion | 20 | $25,999 |
| Invega SustennaPaliperidone Palmitate | 15 | $23,549 |
| LybalviOlanzapine/Samidorphan Malate | 12 | $19,532 |
| Olanzapine-Fluoxetine HclOlanzapine/Fluoxetine Hcl | 43 | $16,779 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,255 | $479,17658 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $2,144 | $402,38325 claims |
| Acadia Pharmaceuticals IncNuplazid | $132 | $197,92628 claims |
| AbbVieVraylar | $1,032 | $145,15691 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $1,418 | $134,49177 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,471 | $96,15157 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $246 | $75,343100 claims |
| Alkermes, Inc.Aristada, Lybalvi | $527 | $51,38525 claims |
| Johnson & JohnsonInvega Sustenna, Risperdal | $668 | $27,28740 claims |
| Axsome Therapeutics, Inc.Auvelity | $715 | $25,99920 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $272 | $8,82018 claims |
| Lilly USA, LLCOlanzapine | $135 | $6,664374 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few behavioral neurology & neuropsychiatry providers in New Yorkon file to place this against a meaningful peer group, so we don't.
Other behavioral neurology & neuropsychiatry in Amherst
- Luca GilibertoGreat Neck$12K
- Sonja BlumNew York$6K
- Lindsey GurinNew York$5K
- Maria Josefa Malaga AragonNew York$493
- Haythum TayebHawthorne$278
- Silky PahlajaniNew York$266
- Miranda MohabirManlius$257
- Mariel DeutschMerrick$124
- Tahsin HasanStony Brook$110
- Jason BrownNew York$68
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.